| Identification | Back Directory | [Name]
Benzeneacetamide, α-[(4-hydroxy-3-methoxyphenyl)methylene]-N-[2-(4-hydroxyphenyl)ethyl]-2,5-dimethoxy- | [CAS]
863193-70-8 | [Synonyms]
FLZ
Fenlean
Benzeneacetamide, α-[(4-hydroxy-3-methoxyphenyl)methylene]-N-[2-(4-hydroxyphenyl)ethyl]-2,5-dimethoxy- | [Molecular Formula]
C26H27NO6 | [MOL File]
863193-70-8.mol | [Molecular Weight]
449.5 |
| Chemical Properties | Back Directory | [Boiling point ]
710.6±60.0 °C(Predicted) | [density ]
1.245±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
8.75±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Fenlean, also known as FLZ, is currently in phase I trials by Institute of Materia Medica, Chinese Academy of Medical Science as a potential treatment of Parkinson's disease. |
|
|